Not yet on Track: Retrospective Chart Analysis Reveals Physician's Treatment Approaches in SLE Fall Short of New EULAR Guidance (ACR Convergence 2024) - Sep 25, 2024 - Abstract #1532; Pres time: Nov 17, 2024; 10:30 AM - 12:30 PM; Location: Hall C; In Person; "Notably, since the previous guidelines update in 2019, anifrolumab received approval for treatment of SLE, and belimumab and voclosporin for LN. 1,263 moderate-to-severe (M/S) adult SLE patient records were collected in collaboration with 256 EU5 rheumatologists via an online survey platform from March through April 2024...That said, the proportion of patients in the US on the recommended lower dose increased by 13 percentage points between 2022 and 2023, without change in EU5.Third, EULAR guidelines recommend rheumatologists should consider adding traditional DMARDs (methotrexate, azathioprine, or mycophenolate mofetil) and/or biologics to patients who fail to respond to HCQ or those who fail to taper to maintenance GC doses of ≤ 5mg... While SLE management practices in the US and EU5 share similarities, there are notable differences, particularly in HCQ. Importantly, both regions show increasing adoption of biologics, especially for steroid-dependent patients...."
Retrospective data • Inflammatory Arthritis • Rheumatology
|
|
Maxine Yarnall1; Ryan Rex2; Sawyer May1
|